AI Judge changed title after evaluation, original title: "Edison Scientific announced a strategic collaboration with Incyte on May 19, 2026, to integrate its Kosmos AI platform across the full drug discovery and development lifecycle"
Incyte becomes first company to integrate the system end-to-end.
Sam Rodriques#1461
We are excited to announce a strategic collaboration with @EdisonSci to employ the Kosmos AI platform across Incyte's discovery and development lifecycle. Read more. https://bit.ly/4dvd37o
Some users praise Edison Scientific's Kosmos AI partnership with Incyte for speeding up drug development after achieving patent successes, while others label the product a failure and question its effectiveness.
No Digg Deeper questions have been answered for this story yet.
We live in a golden age of biology. So why are people still dying from disease?
Because discovery and development move slower than they should.
Today, we’re partnering with Incyte to change that.
Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. @Incyte will be the first company to deploy it across their pipeline.
Work that used to take a team of scientists months now happens in weeks.
Patients can't wait, and neither can we.
More on our collaboration, and our improvements to Kosmos, here:
https://edisonscientific.com/news/building-ai-native-biopharma-announcing-our-partnership-with-incyte-corporation-and-kosmos-for-r-d-teams
We live in a golden age of biology. So why are people still dying from disease?
Because discovery and development move slower than they should.
Today, we’re partnering with Incyte to change that.
Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. @Incyte will be the first company to deploy it across their pipeline.
Work that used to take a team of scientists months now happens in weeks.
Patients can't wait, and neither can we.
More on our collaboration, and our improvements to Kosmos, here:
https://edisonscientific.com/news/building-ai-native-biopharma-announcing-our-partnership-with-incyte-corporation-and-kosmos-for-r-d-teams
We live in a golden age of biology. So why are people still dying from disease?
Because discovery and development move slower than they should.
Today, we’re partnering with Incyte to change that.
Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. @Incyte will be the first company to deploy it across their pipeline.
Work that used to take a team of scientists months now happens in weeks.
Patients can't wait, and neither can we.
Every major pharma company announced an AI partnership in the last three years. Most of them changed nothing.
The press release went out, the stock moved, and the actual R&D pipeline stayed exactly the same.
Edison Scientific just deployed Kosmos across Incyte's full pipeline. Not a pilot. Not a proof of concept. A production system that reads 1,500 papers and writes 42,000 lines of code in a single run!
The difference between this and everything that came before it: receipts. 79% reproducibility. Every conclusion traceable to a specific paper or line of code.
This is the first time I'm looking at an AI deployment in pharma and thinking: this actually changes how drugs get made. Not in theory, or in a pitch deck - but in production, right now, across an entire R&D pipeline.
If AI can compress six months of scientific work into a single day with this level of traceability, the implications for how fast treatments reach patients are massive.
The AI-for-science landscape today looks a lot like coding tools circa 2023: autocomplete/prototyping products that accelerate one step of a long workflow. Useful, but bounded.
@EdisonSci Kosmos is the equivalent of a full-stack coding agent that owns the loop end-to-end, from target discovery through development into commercialization. The @Incyte partnership brings it into the real world, working on a real pipeline and solving real problems. Proud to be backing @SGRodriques and the team!
We live in a golden age of biology. So why are people still dying from disease?
Because discovery and development move slower than they should.
Today, we’re partnering with Incyte to change that.
Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. @Incyte will be the first company to deploy it across their pipeline.
Work that used to take a team of scientists months now happens in weeks.
Patients can't wait, and neither can we.
@SGRodriques I need AI to process all the data for my printer
More on our collaboration, and our improvements to Kosmos, here:
https://edisonscientific.com/news/building-ai-native-biopharma-announcing-our-partnership-with-incyte-corporation-and-kosmos-for-r-d-teams
We live in a golden age of biology. So why are people still dying from disease?
Because discovery and development move slower than they should.
Today, we’re partnering with Incyte to change that.
Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. @Incyte will be the first company to deploy it across their pipeline.
Work that used to take a team of scientists months now happens in weeks.
Patients can't wait, and neither can we.
The Incyte team operates with infectious urgency to bring new medicines to patients. It has been fantastic to collaborate with them.
We are excited to announce a strategic collaboration with @EdisonSci to employ the Kosmos AI platform across Incyte's discovery and development lifecycle. Read more. https://bit.ly/4dvd37o
New product AND gigantic pharma deal
@EdisonSci is absolutely killing it 💪
We live in a golden age of biology. So why are people still dying from disease?
Because discovery and development move slower than they should.
Today, we’re partnering with Incyte to change that.
Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. @Incyte will be the first company to deploy it across their pipeline.
Work that used to take a team of scientists months now happens in weeks.
Patients can't wait, and neither can we.
@SGRodriques Healthcare entering its Formula 1 era 👀
New Kosmos is amazing.
In one of my first conversations with New Kosmos, ideas we came up with together ended up as patent claims less than two weeks later.
The link to apply for early access is here: https://platform.edisonscientific.com/get-kosmos
Buried under all the other stuff they announced :P
@SGRodriques congrats sam! huge breakthrough
We live in a golden age of biology. So why are people still dying from disease?
Because discovery and development move slower than they should.
Today, we’re partnering with Incyte to change that.
Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. @Incyte will be the first company to deploy it across their pipeline.
Work that used to take a team of scientists months now happens in weeks.
Patients can't wait, and neither can we.
**Kosmos (Edison Scientific) is very new** — the big Incyte production deployment was announced yesterday.
Early validation from their arXiv paper (and independent expert review): 79.4% of statements in reports rated accurate; beta users estimate one 20-cycle run ≈ 6 months of PhD-level work. It reads ~1,500 papers, runs large-scale analyses, and outputs ~42k lines of code + traceable reports per run.
**Engine**: multi-agent system with a persistent “world model” for long-running coherence. Iterative cycles of literature synthesis + data analysis + hypothesis generation. Heavy NVIDIA stack (Nemotron Parse, cuML, etc.).
**Moat**: traceability (every claim links to exact paper/code), measured reproducibility, and now real enterprise data flywheel with Incyte for continuous learning. Still early days — strong technical claims but real-world pipeline impact will take time to prove.
@erika_alden_d @EdisonSci Never stop shipping 🚢
@SGRodriques A 10-year drug development cycle was never just a biology problem.
A huge part of it was repetition, process friction, and institutional memory disappearing between programs.
@SGRodriques What gets me isn't the AI part.
It's that a public pharma company put their entire R&D pipeline behind one decision. You don't do that for optionality. You do that when you've already seen something work.
@SGRodriques This gives me immense hope, amazing!
@SGRodriques This is what fixing infrastructure actually looks like. Not a pilot. A full deployment.
@SGRodriques Potential game changer! Congrats on the partnership and the success!
@SGRodriques Great app. I signed up with the service back in November. A hidden gem!!
